Canaccord analyst William Plovanic lowered the firm’s price target on Staar Surgical (STAA) to $28 from $31 and keeps a Hold rating on the shares. Canaccord said they are bullish on the Med-Tech sector heading into 2025 as they expect investor interest to increase given smid-cap valuations continue to remain depressed while M&A has picked up and the IPO market seems to have opened. They highlight how AI is changing the space and are seeing continued interest in value-based care in the US, and believe that med-tech is well positioned to help drive the trend for improving patient outcomes while also reducing overall costs.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on STAA:
- Staar Surgical price target lowered to $23 from $27 at Morgan Stanley
- Staar Surgical price target lowered to $31 from $41 at Canaccord
- Staar Surgical price target lowered to $49 from $53 at BTIG
- STAAR Surgical Posts Strong Q3 2024 Financial Results
- Staar Surgical Achieves 10% Sales Growth, Income Doubles